Company intelligence
Labiotech.eu
Europe’s premier digital media platform for the global biotech industry.
About Labiotech.eu
Labiotech.eu is Europe’s premier digital media platform for the global biotech industry. More than 130,000 monthly biopharma readers rely on Labiotech for insights into the latest innovations in biotechnology and our analysis of a dynamic industry. Subscribe today for access to our daily articles, in-depth content and extensive archive.
Verified activity
Signals from Labiotech.eu
11 published signals
Research & Knowledge
Labiotech.eu published an article by Willow Shah-Neville sharing the journey of patient Andy Brown battling follicular lymphoma affecting around 13,747 people in the UK every year.
Reported by Labiotech.eu
Presence & Recognition
Labiotech.eu announced that BIO-Europe, Europe's flagship biotech partnering conference, is returning to Cologne this November for its 32nd edition with 7 expanded content tracks, a new content-only pass, and over 80% of delegates joining social events.
Reported by Labiotech.eu
Customers & Market
Labiotech.eu reports that the most expensive acquisition was Eli Lilly and Company's $2.875 billion buyout of autoimmune disease-focused Merida Biosciences in August 2026.
Reported by Labiotech.eu
Presence & Recognition
Labiotech.eu featured Dylan Kissane and Per Lundin discussing Evox Therapeutics Ltd's delivery mechanism and pipeline for brain-penetrant gene therapy.
Reported by Labiotech.eu
Strategy & Corporate Development
Labiotech.eu reports that SK Biopharmaceuticals partners with Biohaven for Biohaven’s Kv7 ion channel platform, with Biohaven receiving up to $795 million in upfront and milestone payments.
Reported by Labiotech.eu
Strategy & Corporate Development
Labiotech.eu reports that Roche partners with Simcere Zaiming for tri-specific antibody for B-cell-mediated diseases, with Simcere Zaiming eligible to receive up to $1.530 billion in total payments including $75 million in upfront.
Reported by Labiotech.eu
Strategy & Corporate Development
Labiotech.eu reports that Genentech collaborates with DualityBio to develop next-generation antibody-drug conjugates, with DualityBio receiving $45 million upfront and milestone payments.
Reported by Labiotech.eu
Strategy & Corporate Development
Labiotech.eu reports that Eli Lilly and Company acquired Merida Biosciences for up to $2.875 billion, with Merida Biosciences leading asset MER511 acquired.
Reported by Labiotech.eu
Capital & Finance
Labiotech.eu reports that public companies achieved the best total of the year after attracting an incredible $5.187 billion from just 11 rounds in August 2026.
Reported by Labiotech.eu
Capital & Finance
Labiotech.eu reports that private companies witnessed their worst total of the year so far, raising $1.083 billion from ten rounds in August 2026.
Reported by Labiotech.eu
Presence & Recognition
Labiotech.eu reported on the ESC Congress 2026 in Munich from August 28 to 31, presenting new clinical trial results across cardiovascular disease.
Reported by Labiotech.eu